{
  "kind": "treatment",
  "slug": "ethosuximide-zarontin",
  "type": "anticonvulsant",
  "name": "Ethosuximide (Zarontin)",
  "summary": "An anticonvulsant primarily used for the treatment of absence seizures.",
  "description": "Ethosuximide is a succinimide anticonvulsant that works by reducing T-type calcium currents in thalamic neurons, thereby stabilizing neuronal activity and preventing the abnormal cortical rhythms seen in absence seizures. It is considered the drug of choice for uncomplicated absence epilepsy.",
  "category": "medications/anticonvulsants",
  "tags": [
    "anticonvulsant",
    "absence seizures",
    "epilepsy"
  ],
  "metadata": {
    "drug_classes": [
      "Anticonvulsant",
      "Succinimide"
    ],
    "therapeutic_categories": [
      "Seizure Disorders",
      "Epilepsy"
    ],
    "mechanism_categories": [
      "Other"
    ],
    "administration_routes": [
      "Oral"
    ],
    "prescription_status": "Prescription Required",
    "controlled_substance": false,
    "generic_available": true,
    "brand_names": [
      "Zarontin"
    ],
    "dea_schedule": null,
    "fda_pregnancy_category": "C",
    "age_groups": [
      "Pediatric",
      "Adult"
    ],
    "treatment_duration": [
      "Long-term"
    ],
    "specialty_areas": [
      "Neurology",
      "Pediatric Neurology"
    ],
    "fda_approval_year": 1960
  },
  "clinical_metadata": {
    "primary_indications": [
      "Seizures"
    ],
    "off_label_uses": [
      "Myoclonic seizures (adjunctive)"
    ],
    "contraindications": [
      "Hypersensitivity to ethosuximide or succinimides"
    ],
    "monitoring_required": [
      "CBC",
      "Liver function tests",
      "Renal function"
    ],
    "efficacy_rating": {
      "absence_seizures": 5
    }
  },
  "search_metadata": {
    "searchable_terms": [
      "ethosuximide",
      "zarontin",
      "absence epilepsy",
      "succinimide"
    ],
    "synonyms": [
      "2-ethyl-2-methylsuccinimide"
    ],
    "common_misspellings": [
      "ethosuxamide",
      "ethosuximid"
    ]
  },
  "sections": [
    {
      "type": "indications",
      "items": [
        "Absence seizures"
      ]
    },
    {
      "type": "mechanism",
      "text": "Reduces low-threshold T-type calcium currents in thalamic neurons, suppressing the rhythmic cortical discharges characteristic of absence seizures."
    },
    {
      "type": "dosing",
      "adult": {
        "absence_seizures": "Initial: 500 mg/day; may increase by 250 mg every 4–7 days; usual maintenance: 1–1.5 g/day in 1–2 divided doses"
      },
      "pediatric": "Initial: 250 mg/day; increase by 250 mg every 4–7 days; usual maintenance: 20 mg/kg/day in divided doses",
      "hepatic_impairment": "Use caution; monitor function",
      "renal_impairment": "Use caution; monitor function"
    },
    {
      "type": "dosage_forms",
      "items": [
        "Capsules: 250 mg",
        "Oral solution: 250 mg/5 mL"
      ]
    },
    {
      "type": "onset_duration",
      "text": "Onset within several days to weeks; duration of action is 24 hours (once-daily dosing possible)."
    },
    {
      "type": "adverse_effects",
      "common": [
        "nausea",
        "vomiting",
        "abdominal pain",
        "fatigue",
        "dizziness",
        "headache"
      ],
      "less_common": [
        "rash",
        "pruritus",
        "behavioral changes"
      ],
      "serious": [
        "blood dyscrasias",
        "systemic lupus erythematosus",
        "hepatic dysfunction",
        "suicidal ideation"
      ]
    },
    {
      "type": "warnings",
      "black_box": null,
      "other": [
        "Monitor for behavioral and mood changes",
        "May cause Stevens–Johnson syndrome (rare)",
        "Use caution in patients with liver or kidney disease"
      ]
    },
    {
      "type": "interactions",
      "items": [
        {
          "with": "Valproic acid",
          "risk": "Altered serum levels of both drugs",
          "action": "Monitor levels and adjust dose"
        },
        {
          "with": "CNS depressants",
          "risk": "Enhanced sedation",
          "action": "Use caution"
        }
      ]
    },
    {
      "type": "monitoring",
      "items": [
        "CBC periodically",
        "Liver function tests",
        "Renal function",
        "Seizure frequency and control"
      ]
    },
    {
      "type": "special_populations",
      "pregnancy": "Use if benefits outweigh risks; risk of teratogenicity",
      "lactation": "Excreted in breast milk; use caution",
      "pediatrics": "Preferred first-line for absence seizures",
      "geriatrics": "No specific adjustments, but monitor organ function"
    },
    {
      "type": "tapering",
      "text": "Gradually reduce dose over several weeks to avoid seizure recurrence."
    },
    {
      "type": "clinical_notes",
      "items": [
        "Most effective monotherapy for absence seizures",
        "Less sedating than some other antiepileptics",
        "Gastrointestinal side effects can be minimized by dividing doses or taking with food"
      ]
    },
    {
      "type": "references",
      "items": [
        {
          "label": "Zarontin Prescribing Information",
          "url": "https://www.accessdata.fda.gov/"
        },
        {
          "label": "Epilepsy Foundation",
          "url": "https://www.epilepsy.com/"
        }
      ]
    }
  ],
  "seo": {
    "title": "Ethosuximide (Zarontin): Anticonvulsant for Absence Seizures",
    "description": "Ethosuximide (Zarontin) is an anticonvulsant used primarily for the treatment of absence seizures, acting via T-type calcium channel blockade."
  }
}
